# Diabetic cardiomyopathy from a gut microbiota perspective: research progress and prospects

## TL;DR

This review explores how gut microbiota influences diabetic cardiomyopathy and suggests new treatment approaches.

## Contribution

The paper highlights novel therapeutic strategies targeting gut microbiota for diabetic cardiomyopathy.

## Key findings

- Gut microbiota dysbiosis contributes to diabetic cardiomyopathy through endotoxemia and inflammation.
- Microbial metabolites and immune modulation significantly affect myocardial function in diabetes.
- New therapeutic approaches targeting gut microbiota show promise for treating diabetic cardiomyopathy.

## Abstract

Recent evidence indicates that gut microbiota dysbiosis impairs intestinal barrier function, induces endotoxemia, and consequently triggers systemic inflammatory cascades. Advances in gut microbiota research have further elucidated its critical role in the pathogenesis of diabetes and its complications. This review examines the relationship between diabetic cardiomyopathy and gut microbiota, delineating microbial metabolite-mediated and immunomodulatory influences on myocardial function, while proposing novel therapeutic strategies.